Efficacy of single dose intravenous dexamethasone compared with three-day oral dexamethasone for prevention of pemetrexed-induced skin adverse reactions

Phase 2

• Conditions: pemetrexed-induced cutaneous adverse reactions; pemetrexed; rash; dexamethasone

• Registration Number: TCTR20230111003
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-11
• Study Completion: 2023-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

1. age more than 17
2. no prior exposure to pemetrexed
3. planned to receive single agent pemetrexed
4. ECOG 0-2
5. signed inform consent

Exclusion Criteria

1. history of severe drugs and food allgery
2. active skin diseases
3. systemic steriod use 7 days prior to enrollment
4. on other immunosuppressive drugs
5. chronic kidney disease stage IV
6. uncontrolled diabetes

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Grade 3 and 4 cutaneous adverse reactions 7-21 days after pemetrexed treatment CTCAE

Secondary Outcome Measures

Name	Time	Method
All grade cutaneous adverse reactions 7-21 days after pemetrexed treatment CTCAE